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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: The most common diagnostic finding of autoimmune thyroid disease
(AITD) is the presence of antithyroid antibodies. While autoimmune thyroiditis (AT) is a com-
mon AITD, aspiration cytology is one of the important diagnostic tools of AT.
Methods: We evaluated 116 AT patients with ultrasound-guided aspiration cytology and then
analyzed the correlation between thyroid hormone status and thyroid autoantibodies. This
was a retrospective analysis with prospective collection of data with a mean follow-up period
of 68.8  37.8 months. The patients were classified as either euthyroid, hypothyroid, or hyper-
thyroid (HT). Of the 116 patients, 22 were hypothyroid, 37 were euthyroid, and 57 were HT.
Results: During the follow-up period, 95.5% of the hypothyroid group remained hypothyroid
and only one patient improved to euthyroid. In the euthyroid group, 16.2% progressed to hy-
pothyroid and 83.8% remained euthyroid. In the HT group, 8.7% progressed to hypothyroid,
70.2% progressed to euthyroid, and 21.1% remained HT. Most patients with a high titer of thyro-
globulin antibody (TgAb) will progress to hypothyroid, and patients with a high titer of thyroid
stimulating hormone (TSH) receptor antibody (TRAb) will remain HT. Strong correlationsave no conflicts of interest relevant to this article.
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1040 K.-M. Chou et al.between thyroid functional status and positive number of thyroid autoantibodies were seen in
this study. Patients with all the three antibodies positive had a high prevalence of hyperthy-
roidism.
Conclusion: In our study, most patients were HT; this may be because of the early diagnosis
and treatment of AT in our clinic. Although antithyroperoxidase antibody (TPOAb) is a hallmark
antibody of HT, it cannot predict the initial presentation and clinical outcome.
Copyright ª 2013, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Autoimmune thyroiditis (AT), alternatively known as
chronic lymphocytic thyroiditis or Hashimoto’s thyroiditis,
is an autoimmune disorder characterized by an inflamma-
tory infiltration of lymphocytes that replaces the thyroid
parenchyma.1,2 These processes may lead to thyroid cell
damage, cell destruction, and subsequently to impaired
thyroid hormone production and clinical thyroid dysfunc-
tion.2 This thyroid dysfunction may progress to a euthyroid,
hyperthyroid (HT) and then hypothyroid state, which will
be the end of AT, based on the cell destruction character-
istics and immune-mediated loss of follicular cells.2,3 At the
time of diagnosis, the thyroid function test shows varia-
tionsdmostly euthyroid or hypothyroid, and rarely HT.4
Hypothyroidism is thought to be a permanent sequel of
AT.5 A multicenter study showed that 35.3% of euthyroid
patients may become hypothyroid within a mean follow-up
period of 5 years.6 However, there is no information about
the clinical outcome of initial hyperthyroidism in AT
patients.
In our study, the most common autoantibodies encoun-
tered include circulating autoantibodies to thyroglobulin
(TgAb), antithyroperoxidase antibody (TPOAb), and thyroid
stimulating hormone-R (TSH-R) antibody-thyroid binding
inhibitory immunoglobulin (TRAb).7 These autoantibodies
are the hallmarks of AT.8 They are considered to be able to
induce HT or hypothyroid states, depending on their ac-
tivity.9 Controversy exists as to whether these autoanti-
bodies play an important role in the pathogenesis, or occur
merely as an epiphenomenon of thyroid tissue destruction.3
The aims of the present study were to assess and confirm
the correlation of these autoantibody titers and the long-
term clinical process of AT.Patients and methods
Study population
A total of 116 patients were diagnosed with AT on the basis
of fine-needle aspiration cytology (FNAC) criteria using ul-
trasound guidance and then follow up in the endocrinology
department of Chang Gung Memorial Hospital (CGMH) in
both Keelung and Taipei from January 1999 to December
2010. This study adheres to the Declaration of Helsinki and
was approved by the Ethics Committee of the institutional
Review Board at Chang Gung Memorial Hospital. In this
study, we excluded the post-thyroidectomy patients, those
who undergo radioactive iodide therapy, those with auto-
immune diseases such as pernicious anemia, systemic lupuserythematous (SLE), rheumatoid arthritis (RA), type 1 dia-
betes mellitus, or any evidence of co-existent pregnancy.
We also excluded Graves’ disease (GD) patients using the
typical cytology findings. Graves’ cytology is characterized
by follicular hyperplasia, which is present in small- to
medium-sized monolayer sheets, and a patchy (multifocal)
lymphocytic infiltration, with background smears that
contain scanty, diffusely distributed, and weakly stained
colloid.10e12
Thyroid ultrasound and FNAC
A real-time scanner with a 10-MHz ASU-36WL-10 annular-
array transducer (ALOKA, Tokyo, Japan) was used for ul-
trasound (US) measurements. A longitudinal and transverse
view of the thyroid was detected.
FNAC was performed with 23e25 gauge needles, con-
nected to a 10-mL disposable syringe and from a non-
nodule area (Fig. 1). The aspirated sample was expressed
on frosted-end glass slides, air-dried, and stained using the
Romanowsky-based method described by Riu.13,14 All US
and cytological results were interpreted by two attending
physicians from the endocrinology division at CGMH.
Definition of AT by FNAC
AT is characterized by the predominance of lymphoid cells,
and these lymphoid cells chiefly consist of lymphocytes and
centroblasts15 (Fig. 2A and B). Various abundant plasma
cells are noted (Fig. 2C and D). Colloid is scantly or entirely
absent.15 Normal thyroid tissue is replaced by a dissemi-
nated oxyphilic change (Hu¨rthle cells) of follicular cells or
degenerative follicular cells15(Fig. 2E,F), and cell debris is
often seen.
After the patients were diagnosed with AT by US-guided
aspiration cytology, we retrospectively reviewed their
thyroid function status when they were first diagnosed with
thyroid disorders, according to their hospital files. The
patients were then recalled and the thyroid hormone status
was followed up prospectively. All patients agreed to
participate in the observational study and have been fol-
lowed up in our endocrine clinic until now. During the
follow-up period, we completed all of the thyroid autoan-
tibody analyses (TPOAb, TgAb, and TRAb). The thyroid
function status (FT4 and TSH) of all participants was
measured every 3e6 months until the end of the study.
Clinical details on sex, age at onset, total time of illness,
and follow-up duration in our endocrine clinic were also
collected.
The 116 patients were divided into three groups, based
on thyroid function: euthyroid (both FT4 and TSH levels
Figure 2 Typical fine-needle aspiration cytology smears of Hashimoto’s thyroiditis. (A,B) Abundant small lymphocytes (black
arrow) and centroblasts (red arrow) (Riu stain, 200 and 400). (C,D) Plasma cells (black arrows) (Riu stain, 200 and 400). (E,F)
Hu¨rthle cells (black arrow) and degenerative follicular cells (red arrow) (Riu stain, 200 and 400).
Figure 1 Sonography of HT. (A) Longitudinal and (B) transverse sonogram of HT without the nodule. (C) Longitudinal and (B)
transverse sonogram of HT with the left lobe nodule. HT Z hyperthyroid.
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Figure 3 Follow-up design.
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thyroxine treatment for more than 12 months), hypothyroid
(low FT4 with elevated TSH with or without thyroxine
replacement therapy), subclinical hypothyroid (normal FT4
with elevated TSH ) enrolled into the hypothyroid group, HT
(elevated thyroid hormone levels in the face of suppressed
TSH or euthyroid under antithyroid treatment), and sub-
clinical HT (normal FT4 with low TSH level) enrolled into
the HT group.
The same classification was used to define thyroid
functional status up to the end of the study (at re-
evaluation). We maintained medication for hypothyroid
patients and discontinued antithyroid drugs for HT patients
when they achieved a euthyroid status in the follow-up
period.
Laboratory measurements
Assessment of TPOAb was by competitive immunoassay
using the Abbott AxSYM immunoassay autoanalyzer (Abbott
Diagnostics, Abbott Park, IL, USA), which performed an
anti-TPOAb test that used a “microparticle immunoassay”
as a principle and a value >12 IU/mL was considered
positive.
We used a radioreceptor assay kit (RRA), manufactured
by CisBio (Saclay, Essonne, France), for the measurement
of TSH receptor autoantibodies (TRAb) in human serum.
TRAb in patient’s sera was allowed to interact with TSH
receptor coated onto plastic tubes. Bound TRAb was
detected by its ability to inhibit the binding of 125I-labelled
TSH to the receptor-coated tubes; TRAb levels were read
off a standard curve, and the results were expressed as an
inhibition of the TSH binding index (>15% was positive).
The TgAb test was performed with a Serodia ATG kit
manufactured by FUJIREBIO Diagnostics (Tokyo, Japan)
using gelatin particle agglutination as an assay principle
(>1:100 was considered positive). We completed the au-
toantibodies measurement once only in our prospectively
collected data period.
Statistical analysis
Statistical analysis was carried out with SPSS for Windows
version 16.0 (SPSS Inc., Chicago, IL, USA). The Chi-square
test was used in comparisons of different study groups and
the analysis of variance (ANOVA) test for comparisons be-
tween autoantibodies. A p value <0.05 was considered to
be significant in all tests. The data were expressed as
mean  standard deviation (SD).
Results and observations
A total of 116 (106 females, 10 males) AT patients
(confirmed by fine needle aspiration) were selected for the
present study. The mean age at the initial status was
42.2  12.0 (range: 16-77 years old) and the total mean
follow-up period in our endocrine outpatient clinic was 68.8
months. The follow-up design and hormonal status of the
patients are shown in Fig. 3.
The hormonal status of the patients at initial status and
at the time of re-evaluation are summarized in Fig. 4. Aretrospective analysis of hospital files showed that the
initial clinical presentations of our 116 study patients were
as follows: hypothyroid status in 22 patients, euthyroid in
37, and HT in 57. During the follow-up period in our endo-
crine clinic, 21 patients (95.5%) in the hypothyroid group
(mean follow-up: 64.1 months) remained hypothyroid and
just one patient (4.5%) improved to euthyroid. In the
euthyroid group (mean follow-up: 57.7 months), six pa-
tients (16.2%) progressed to a hypothyroid status and 31
(83.8%) remained euthyroid. In the HT group (mean follow
up 77.7 months), five patients (8.7%) progressed to hypo-
thyroid, 40 (70.2%) progressed to euthyroid, and 12 (21.1%)
remained HT.
Baseline laboratory characteristics and thyroid autoan-
tibodies versus the thyroid functional status of patients at
initial status were compared (Table 1). Neither sex nor body
mass index (BMI) were significantly different among the
different thyroid functional statuses. The hypothyroid
group patients were relatively older than the euthyroid and
HT patients (pZ 0.04). Significantly shorter follow-up time
was noted in the euthyroid group (p Z 0.03). There were
more male subjects in the HT group than in the other
groups, but without clinical significance. In terms of thyroid
autoantibodies, 52% (54/103) of the initially HT patients
were TPOAb positive with a mean value of 583.57  59.69,
78.3% (36/46) were TRAb positive with a mean value of
29.79  2.22, and the p values were significant (0.01,
<0.001). TgAb was positive in 46.8% (29/62) of patients
with a mean value of 19927.81  14729.74; however, this
was insignificant (p Z 0.87). After adjusting for the age at
diagnosis (Table 2), only TRAb was found to be significantly
and highly positive in the HT subjects [odds ratio (OR): 7.87
with 95% confidence interval (CI) Z (3.03, 20.45)]; TPOAb
and TgAb were not significantly different.
Correlations between the numbers of thyroid autoanti-
bodies and initial thyroid functional status are shown in
Table 3. Twenty-seven cases were positive for all the three
antibodies, 52 for two antibodies, and 33 for one antibody;
only four cases were nonantibody positive.
In the hypothyroid group, three patients were negative
for all the three autoantibodies; eight had one autoanti-
body, and 75% (6/8) were TPOAb-positive; 10 had two au-
toantibodies positive, and all of them were TPOAb þ TgAb-
positive; only one patient had three autoantibodies. In the
euthyroid group, only one patient was negative for all the
three autoantibodies; 14 patients had one autoantibody,
and 78.6% (11/14) were TPOAb-positive. Among 18 patients
positive for two autoantibodies, 83.3% (15/18) were TPOAb
Figure 4 Follow-up design and hormonal status of patients.
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Four patients were positive for three autoantibodies. In the
HT group, none of the patients were negative for all the
three antibodies; 11 were positive for one autoantibody and
90.9% (10/11) were TPOAb; 24 were positive for 2 autoan-
tibodies, 41.7% (10/24) were TPOAb and TgAb, and 58.3%
(14/24) were TPOAb- and TRAb-positive; 22 were positive
for all the three autoantibodies.
Comparisons of clinical parameters and thyroid autoan-
tibodies with thyroid functional status at initial status and
re-evaluation are shown in Table 4.
Two clinical variations (hypothyroid and euthyroid) from
the initial status of the euthyroid group were found at theTable 1 Comparison of baseline laboratory characteristics and
initial status.
Total Hypothyroid
No. of subjects 116 22
Age (y) 42.2  12 48.6  12.2
Sex (female/male) 106/10 22/0
F/U time (mo) 68.8  37.8 64.1  36.2
BMI (kg/m2) 23  2.6 23.2  2.6
TPOAb (12) 103 17
TRAb (15) 46 2
TgAb (100) 62 12
Values are given as mean  SD.
BMI Z body mass index; F/U Z follow-up; SD Z standard deviation
antibody; TRAb Z thyroid stimulating hormone-receptor antibody.time of re-evaluation. Most patients with a high titer of
TgAb had progressed to hypothyroid. In the HT group at the
initial status, three variations of thyroid functional statuses
were found at re-evaluation (hypothyroid, euthyroid, and
HT). A significantly shorter follow-up period (45 months)
was found in the re-evaluated HT group. Most patients with
a high titer of TgAb had progressed to hypothyroid. Patients
with a high titer of TRAb remained HT significantly.
Discussion
GD and AT are known as AITDs, which are classic examples
of organ-specific autoimmune conditions.3 Hyperthyroidthyroid autoantibodies versus the thyroid functional status at
Euthyroid Hyperthyroid p
37 57
41.6  14.9 40.0  13.3 0.0439
35/2 49/8 0.0962
57.7  39.7 77.7  35.5 0.0336
22.9  2.8 23.1  2.6 0.5435
32 54 0.0120
8 36 <0.0001
21 29 0.8710
; TgAb Z thyroglobulin antibody; TPOAb Z antithyroperoxidase
Table 2 Comparison of thyroid autoantibodies after being adjusted for the age of diagnosis.
Variable Initial (HYPO/EU) p Initial (HYPER/EU) p
OR (95% CI) OR (95% CI)
Age 1.04 (1.00, 1.08) 0.0812 0.99 (0.96, 1.02) 0.4700
TPOAb 0.23 (0.06, 1.00) 0.0504 10.08 (1.02, 99.86) 0.0501
TRAb 0.15 (0.03, 0.70) 0.0155 7.87 (3.03, 20.45) <0.0001
TgAb 1.03 (0.36, 2.90) 0.9600 0.70 (0.28, 1.76) 0.4500
CI Z confidence interval; EU Z euthyroid; HYPER Z hyperthyroid; HYPO Z hypothyroid; OR Z odds ratio; TgAb Z thyroglobulin
antibody; TPOAb Z antithyroperoxidase antibody; TRAb Z thyroid stimulating hormone-receptor antibody.
1044 K.-M. Chou et al.status is the most common clinical presentation in GD and
results from an unregulated synthesis of thyroid hormone;
spontaneous remission occurs in approximately 30% of pa-
tients.16 Three efficacious treatments (medical, surgical,
and radioiodine therapies) are available for the HT status in
GD, and the clinical prognosis varies according to the
treatment.16 However, only AT patients were involved in
this study. AT is characterized by lymphocyte infiltration
into the thyrocytes and usually has autoantibodies to thy-
roid antigens.7 The pathogenesis of AT is thought to involve
a complex interaction between thyroid autoantibodies,
thyroid cells, and environmental modulating factors.2
Anti-TPOAb may be implicated in the pathogenesis of
AITD by: (1) activating the complement cascade and
inducing complement-mediated tissue damage to thyroid
cells17 and (2) inducing antibody-dependent cell-mediated
cytotoxicity, with TPOAb titers correlating with the severity
of lymphocyte infiltration, regardless of the presence or
absence of hypothyroid.18 A patient with advanced AT has
extremely high titers of TgAb.19 Nearly 100% of genetically
susceptible animals that were fed a high-iodine diet
became TgAb-positive.20 In a 5-year follow-up study of 3018
patients, Li Y et al21 found that a high iodine intake by
subjects who were TPOAb- and TgAb-positive at the base-
line was a more common risk factor for developing hypo-
thyroid status among this group than among seronegative
patients. The mechanism behind this phenomenon may be
that thyroglobulin combined with a high iodine intake en-
hances the antigenicity of thyroglobulin and promotes
lymphocyte proliferation.22 TSH exerts its activity by
binding to the extracellular domain of TSH-receptor, a G
protein-coupled 7-transmembrane domain receptor located
in the basolateral membrane of thyroid follicular cells.23
TSH receptors stimulating or blocking antibodies (TRAb),Table 3 Correlation between the number of thyroid autoantibo
Antibodies number 0 1
TPO-Ab TRAb TgAb Total no. TPO
Hypothyroid 3 6 1 1 8 0
Euthyroid 1 11 1 2 14 3
Hyperthyroid 0 10 1 0 11 14
0 Z no antibody; 1 Z one antibody (þ); 2 Z two antibodies (þ); 3 Z
TgAb Z thyroglobulin antibody; TPOAb Z antithyroperoxidase antibowhich may interfere with the normal receptor function,
influence the action of TSH.24 They are considered to
induce HT or hypothyroid states, depending on their
activity.24
Most of our 116 patients were female (91.4%), which is
compatible with the high prevalence of AITD in female
patients. Variations in thyroid functional status (euthyroid,
hypothyroid, and HT) in the past history of the AT patients
examined here were noted, which was compatible with
previous studies.25 A previous study of 23 children demon-
strated that alterations in thyroid function and structure
can frequently be observed in overweight or obese chil-
dren.26 In a study of 88 patients, TSH levels were signifi-
cantly higher in overweight/obese subjects than in those at
a normal weight.23 However; this was not a concern in our
study, since the body mass index (BMI) of our patients was
23  2.6 kg/m2, and none were overweight or obese. Most
of our patients were HT; this may be due to the early
diagnosis and treatment of AT in our clinic. In the course of
follow-up, the variations were dynamic. Although most of
the euthyroid patients remained euthyroid and only 16.2%
progressed to hypothyroid status, most of the HT patients
progressed to a euthyroid state within an average 87.9
months of follow-up, and only 21.1% remained HT. How-
ever, the follow-up period (45 months only) of this HT group
was significantly short. We hypothesized that if follow-up
had been maintained, these persistently HT patients
might have progressed to a euthyroid or hypothyroid state.
Almost all hypothyroid patients remained hypothyroid, and
only one patient (4.5%) improved to euthyroid in an average
5-year follow-up. This runs counter to the result of a pre-
vious study of adult AT patients that had a recovery rate
from hypothyroid status of 40% within 10.5 years of follow-
up.27 This low incidence of improvement in our study maydies and the initial thyroid functional status.
2 3
Ab þ TRAb TPOAb þ TgAb TRAb þ TgAb Total no.
10 0 10 1
15 0 18 4
10 0 24 22
three antibodies (þ).
dy; TRAb Z thyroid stimulating hormone-receptor antibody.
Table 4 Comparison of clinical parameters and thyroid autoantibodies with thyroid functional status at initial status and at re-
evaluation.
At initial status Re-evaluated Age BMI F/U time TPOAb TRAb TgAb
Euthyroid
(n Z 37)
Hypothyroid (n Z 6) 45.0  18.9 22.9  2.7 78.0  32.9 784.2  232.9 0 1242.7  1034.1*
Euthyroid (n Z 31) 40.9  14.4 22.9  2.9 53.8  40.1 409.5  87.4 5.7  1.5 865.9  223.6
Hyperthyroid
(n Z 57)
Hypothyroid (n Z 5) 35.8  17.8 23.5  4.0 74.4  32.2 910.9  174 35.7  16.4 409800  327640*
Euthyroid (n Z 40) 40.9  12.2 23.0  2.6 87.9  30.9 525.9  65.4 23.1  4.3 1549.1  705.1
Hyperthyroid (n Z 12) 38.5  17.8 23.1  1.8 45.0  33.2 727.6  129.1 51.5  4.7* 525.7  62.4
Values are given as mean  SE.
*p < 0.05.
BMIZ body mass index; F/UZ follow-up; SEZ standard error; TgAbZ thyroglobulin antibody; TPOAbZ antithyroperoxidase antibody;
TRAb Z thyroid stimulating hormone-receptor antibody.
Thyroid function and autoantibodies in autoimmune thyroiditis 1045be related to the starting time of treatment with thyroxine
and the shorter treatment period. In our study, we started
treatment during the overt hypothyroid state, not from a
subclinical hypothyroid status, and the average treatment
time was only 5.3 years. In previous studies, thyroxine
therapy had no effect on thyroid function in euthyroid pa-
tients with AT4 but may have affected the improvement of
thyroid function in subclinical or overt hypothyroid pa-
tients. We suspect that if we had treated these hypothyroid
patients earlier or for a longer time, the rate of recovery to
a euthyroid state would have been better.
In the current study, patients at an older age seemed to
be more frequently hypothyroid at the time of diagnosis;
this may be due to the longer duration of disease before
diagnosis. Positivity of all the three autoantibodies, espe-
cially TRAb, and male sex may be possible risk factors for a
HT state at diagnosis. The initial high titer of TgAb may be
predictive for a future hypothyroid status and a high TRAb
titer may be a presentation of persistent hyperthyroidism.
This is consistent with a previous study of 50 patients with
newly diagnosed HT at Beijing University, which indicated
that patients with high-avidity TgAb might be at high risk of
developing subclinical, even overt, hypothyroidism.28
However, in our study, TPOAb was highly positive and a
hallmark antibody of AT, but it could not predict the initial
presentation and clinical outcome. Researchers have re-
ported that although positivity for TPOAb is an important
marker of AT, in clinical practice, the quantitative mea-
surement of the TPOAb titer may not be mandatory for the
follow-up of the disease.29
In our study, we found a strong correlation of thyroid
functional status with positive number of thyroid autoan-
tibodies. Only four patients (three hypothyroid, one
euthyroid) were negative for all the three autoantibodies.
One AT patient without serologic evidence of an autoim-
mune disorder was found to have several intrathyroidal
human monoclonal antibodies (antibodies against thyro-
globulin, thyroid microsome, thyroid membrane, and
thyrotropin).30 Our four seronegative patients may have
been producing antithyroid antibodies in the thyroid glands
without evidence of a peripheral immune response.
Patients with all the three antibodies positive have a
high prevalence of hyperthyroidism, and most of them will
likely remain HT in the future. Hyperthyroid patients have a
high prevalence of TPOAb- and TRAb-positive, compared to
TPOAb and TgAb-positive in hypothyroid and euthyroidpatients. Our study was limited by the small population of
male subjects.
Conclusion
AT is the disease characterized by a dynamic course. Vari-
ations in thyroid functions were observed during follow-up.
It could be hyper-, hypo-, or euthyroidism during the pa-
tient’s life span, however, most of them will be expected to
be euthyroid life long. A previous study shows rarely HT at
the time of diagnosis. However, this was not uncommon in
our studydmost patients were HT; this condition may be
due to the early diagnosis and treatment of HT in our clinic.
Most of the patients with a high titer of TRAb autoantibody
were HT at the initial clinical presentation, and most of
them remained HT after a mean follow-up of 77.7 months.
A high titer of TgAb could be a possible predictive of hy-
pothyroidism in the clinical outcome of AT. The results of
this study are subject to some limitations. First, the sample
number and unhomogenized characteristics of the study
subjects might confound the study results. Second, this was
a retrospective analysis. The lack of a control group or
effective intervention for comparison might limit the power
of the study. Although TPOAb is a hallmark antibody of AT,
it cannot predict the initial presentation and clinical
outcome. The number of positive autoantibodies may well
be an additive predictor of further clinical status.
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